Organon & Co. (NYSE:OGN) Given Average Recommendation of “Reduce” by Brokerages

Shares of Organon & Co. (NYSE:OGN) have earned a consensus rating of “Reduce” from the seven analysts that are presently covering the company, MarketBeat.com reports. Five analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $8.50.

OGN has been the topic of a number of research reports. JPMorgan Chase & Co. reduced their target price on shares of Organon & Co. from $14.00 to $12.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 11th. Morgan Stanley reduced their price objective on Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 11th. Zacks Research cut Organon & Co. from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Barclays increased their price target on Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 24th. Finally, Wall Street Zen downgraded Organon & Co. from a “buy” rating to a “hold” rating in a report on Saturday, January 31st.

Institutional Trading of Organon & Co.

A number of hedge funds have recently bought and sold shares of OGN. Royal Bank of Canada increased its holdings in shares of Organon & Co. by 53.4% in the 1st quarter. Royal Bank of Canada now owns 360,862 shares of the company’s stock valued at $5,374,000 after acquiring an additional 125,648 shares during the period. Goldman Sachs Group Inc. boosted its position in Organon & Co. by 126.4% during the first quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company’s stock valued at $21,370,000 after purchasing an additional 801,307 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Organon & Co. by 2.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,042,991 shares of the company’s stock valued at $15,530,000 after purchasing an additional 26,640 shares during the last quarter. Focus Partners Wealth raised its holdings in Organon & Co. by 33.2% in the first quarter. Focus Partners Wealth now owns 55,875 shares of the company’s stock worth $832,000 after purchasing an additional 13,925 shares in the last quarter. Finally, AlphaQuest LLC lifted its position in shares of Organon & Co. by 64,378.6% during the second quarter. AlphaQuest LLC now owns 18,054 shares of the company’s stock valued at $175,000 after buying an additional 18,026 shares during the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Performance

Shares of Organon & Co. stock opened at $7.14 on Monday. The stock’s fifty day moving average is $7.99 and its two-hundred day moving average is $8.46. The company has a market capitalization of $1.86 billion, a PE ratio of 9.99, a price-to-earnings-growth ratio of 0.66 and a beta of 0.61. The company has a quick ratio of 1.23, a current ratio of 1.82 and a debt-to-equity ratio of 11.47. Organon & Co. has a 52 week low of $6.18 and a 52 week high of $16.08.

Organon & Co. (NYSE:OGN) last issued its earnings results on Thursday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.73 by ($0.10). The company had revenue of $1.51 billion for the quarter, compared to analysts’ expectations of $1.52 billion. Organon & Co. had a net margin of 3.01% and a return on equity of 122.01%. The firm’s revenue for the quarter was down 5.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.90 earnings per share. As a group, analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 12th. Stockholders of record on Monday, February 23rd will be given a $0.02 dividend. This represents a $0.08 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Monday, February 23rd. Organon & Co.’s dividend payout ratio is presently 11.27%.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.